Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma. - Wikidata - awgldk - TriplyDB

Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.

Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.

http://www.wikidata.org/entity/Q37086039

about

Establishment and validation of a two-step screening scheme for improved performance of serological screening of nasopharyngeal carcinoma.

P2860

Q52685801-0C77EDFC-C248-4B02-952A-42C39895B506

P2860

Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.

http://www.wikidata.org/entity/Q37086039

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Epstein-Barr virus glycoprotei ...... s of nasopharyngeal carcinoma.

@en

Epstein-Barr virus glycoprotei ...... s of nasopharyngeal carcinoma.

@nl

type

label

Epstein-Barr virus glycoprotei ...... s of nasopharyngeal carcinoma.

@en

Epstein-Barr virus glycoprotei ...... s of nasopharyngeal carcinoma.

@nl

prefLabel

Epstein-Barr virus glycoprotei ...... s of nasopharyngeal carcinoma.

@en

Epstein-Barr virus glycoprotei ...... s of nasopharyngeal carcinoma.

@nl

P1433

Q37086039-9A89EEBB-38ED-403D-A19F-A91F0883F093

P1476

Q37086039-C373FD8C-6DCB-4872-BF63-B91021BC9AAC

P2093

Q37086039-0AAB74FD-67FB-4886-BD56-705105C0CFF0

Q37086039-43B59BD5-DCCB-412A-A2CB-F6F4B4F45012

Q37086039-446132C1-3D6B-41C9-A684-479342809AF9

Q37086039-6036494A-20BE-4944-8F3E-B4523231A279

Q37086039-9DC15E46-9696-4510-B673-D071E9081B2A

Q37086039-B92B5807-6764-409C-BC42-06335F065475

Q37086039-C1A7D516-EA1F-4171-BBA4-6C9616D009B6

Q37086039-C7CB0A2D-C84A-4750-AC3F-3F1EC7ACB84D

Q37086039-E7AF26B5-0660-4EAF-AA0E-3E3172DECA19

Q37086039-EA18A232-1BAB-4289-A9FC-E28784208B15

P2860

Q37086039-0790CA2B-E209-4557-912E-0906B204898C

Q37086039-0C517DF4-A420-4EF6-B5B7-26C97A504A44

Q37086039-0D431380-9022-46D9-A5C8-DEC5176CBAF3

Q37086039-0F2AE7AC-008E-4D42-8106-16F98352E814

Q37086039-142CF116-6D1E-44FF-8EDA-07CDBE459C51

Q37086039-15EEA552-7EB7-4366-95CB-741CE0AF102A

Q37086039-1F9FE608-3248-4EAB-8F96-3DF03991F876

Q37086039-2690EBAC-5970-47AF-96A9-EC40F5081225

Q37086039-3002F25C-4E22-4820-ABF8-990CBE8086CB

Q37086039-3457E320-C482-426B-8D45-077004C25D78

P304

Q37086039-8D46E40A-6B1E-46D6-9F4C-AE9AA92C30A3

P31

Q37086039-F7433752-35FD-48DF-BAFF-A4514C05765E

P356

Q37086039-BE63C5F1-1D44-4225-8F3A-C578A595C542

P407

Q37086039-C6744445-8CCE-46C5-A9A8-F9788A3358A9

P433

Q37086039-CD1D3873-3BB0-49A2-8FB8-3567278E7112

P478

Q37086039-89B21AFE-B145-4660-A8EE-A9999469B8B4

P577

Q37086039-42D8A408-932C-47C5-8D4B-8C2C34BEC092

P698

Q37086039-00D51C18-17EC-4DEC-A390-B724EDCD1D6B

P921

Q37086039-75583797-AD18-4BA9-837C-D7E01CBEE7B8

P932

Q37086039-6F44CEA2-A1CC-436B-B9F2-F329CDAF0548

P356

ONCOTARGET.7688

P1433

P1476

Epstein-Barr virus glycoprotei ...... s of nasopharyngeal carcinoma.

@en

P2093

Hua Zhang

http://www.w3.org/2001/XMLSchema#string

Lin-Quan Tang

http://www.w3.org/2001/XMLSchema#string

Mu-Sheng Zeng

http://www.w3.org/2001/XMLSchema#string

Qian Zhong

http://www.w3.org/2001/XMLSchema#string

Qiu-Yao Zeng

http://www.w3.org/2001/XMLSchema#string

Rui-Chen Li

http://www.w3.org/2001/XMLSchema#string

Wan-Li Liu

http://www.w3.org/2001/XMLSchema#string

Xiao-Ming Huang

http://www.w3.org/2001/XMLSchema#string

Yan Li

http://www.w3.org/2001/XMLSchema#string

Yong Du

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex

Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease.

Nasopharyngeal carcinoma incidence and mortality in China in 2010.

Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma.

Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay

Mapping regions of Epstein-Barr virus (EBV) glycoprotein B (gB) important for fusion function with gH/gL.

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.

Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion.

Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma.

Estimation of cancer burden in Guangdong Province, China in 2009.

P304

16372-16383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.7688

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27093005

http://www.w3.org/2001/XMLSchema#string

P921

Epstein–Barr virus

P932

4941321

http://www.w3.org/2001/XMLSchema#string